MMRN2

MMRN2 (EndoGlyx-1) is a pan-endothelial cell-surface extracellular matrix glycoprotein that acts as an angiostatic regulator controlling vascular maturation, stability, and barrier integrity (PMID:11559704, PMID:7933987, PMID:31422156). Structurally it is a ~500 kDa disulfide-bonded complex built from a single ORF encoding an N-terminal EMI domain, a central coiled-coil region, and a C-terminal C1q-like domain, with all subunits exposed on the endothelial surface (PMID:11559704). It restrains angiogenesis by directly binding VEGF-A (Kd ~50 nM), sequestering it from VEGFR1/VEGFR2 and thereby impairing endothelial migration, vessel network formation, and tumor growth (PMID:22020326). MMRN2 is the extracellular ligand for the group 14 C-type lectins CLEC14A, CD93, and CD248: its non-glycosylated coiled-coil region engages CLEC14A and CD93 (via CD93 residue F238), while CD248 binds a distinct, non-competing region, allowing CLEC14A and CD248 to simultaneously bridge the endothelial-pericyte interface (PMID:25745997, PMID:28912033, PMID:28671670). Through CD93 the complex localizes to endothelial filopodia and drives β1 integrin activation, FAK phosphorylation, and fibronectin fibrillogenesis to support vascular maturation (PMID:29763414). MMRN2 maintains junctional stability by suppressing VEGFR2 Tyr951/Tyr949 phosphorylation, Src activation, and VE-cadherin phosphorylation; its loss causes junctional instability, increased permeability, and defective tumor vasculature (PMID:31422156). Its angiostatic deposition is relieved during angiogenic stimulation through MMP-9-mediated proteolytic processing, and its abundance is post-transcriptionally tuned by miR-1910-5p (PMID:28435016, PMID:37040097). Beyond the vasculature, MMRN2 signals through CD93 in cortical neural stem cells to activate a β-Catenin→ZFP503 cascade that represses Gfap transcription and astrogenesis (PMID:32291340).

1. 1994 Medium

   Establishing whether a defining endothelial surface marker existed, EndoGlyx-1/MMRN2 was identified as an endothelial-restricted high-molecular-weight glycoprotein, fixing it as a pan-endothelial protein.

   Evidence Monoclonal antibody (mAbH572) immunochemical characterization across endothelial and non-endothelial cells

   PMID:7933987

   Open questions at the time

   • Molecular identity and sequence not yet defined
   • No function assigned beyond expression pattern
2. 2001 High

   To define the protein's molecular architecture, cloning revealed a single ORF producing a disulfide-bonded multi-subunit complex with EMI, coiled-coil, and C1q-like domains, providing the framework for all later domain-function mapping.

   Evidence Protein purification, peptide sequencing, cDNA cloning, and bioinformatic domain analysis

   PMID:11559704

   Open questions at the time

   • No ligands or receptors identified
   • Functional role of individual domains unknown
3. 2011 High

   Addressing how a matrix protein could be angiostatic, MMRN2 was shown to directly bind VEGF-A and sequester it from VEGFRs, establishing a growth-factor-trapping mechanism.

   Evidence Binding affinity measurement, endothelial migration/tube assays, VEGFR phosphorylation, and tumor xenografts

   PMID:22020326

   Open questions at the time

   • Domain of MMRN2 mediating VEGF-A binding not mapped
   • Receptor-side mechanism beyond ligand sequestration not addressed
4. 2013 Medium

   Searching for endothelial matrix partners, secretome proteomics flagged CLEC14A as an MMRN2 interactor, nominating a receptor class for follow-up.

   Evidence SILAC quantitative proteomics of the endothelial secretome during morphogenesis

   PMID:23979707

   Open questions at the time

   • Interaction not directly validated biochemically in this study
   • No functional consequence established
5. 2015 High

   To test the functional relevance of the CLEC14A interaction, blocking the CLEC14A-MMRN2 bond was shown to impair sprouting and tumor vasculature, establishing a pro-angiogenic receptor-ligand axis.

   Evidence Pull-down/Co-IP, blocking antibody, sprouting and aortic ring assays, clec14a-/- mouse tumor models

   PMID:25745997

   Open questions at the time

   • Binding region on MMRN2 not yet mapped
   • Downstream signaling not defined
6. 2017 High

   To resolve the receptor repertoire and binding architecture, MMRN2 was shown to bind CLEC14A, CD93, and CD248 — with CLEC14A/CD93 sharing the coiled-coil site (CD93 F238) and CD248 occupying a distinct, simultaneously-engageable site — defining a multi-receptor scaffold spanning the endothelial-pericyte interface.

   Evidence Direct binding, site-directed mutagenesis, competition assays, molecular docking, adhesion/migration assays

   PMID:28671670 PMID:28912033

   Open questions at the time

   • Intracellular signaling downstream of each receptor not fully resolved
   • Stoichiometry of multi-receptor complexes unknown
7. 2017 Medium

   To explain how angiostatic MMRN2 is overcome during active angiogenesis, MMP-9 was shown to proteolytically process deposited MMRN2, correlating with increased endothelial migration.

   Evidence MMP cleavage assays, qRT-PCR, migration assays, MMP-9 inhibitor rescue, tumor section immunofluorescence

   PMID:28435016

   Open questions at the time

   • Cleavage sites not mapped
   • Fate and activity of cleavage fragments not characterized
8. 2018 High

   To define the maturation-promoting output of the CD93 axis, the CD93-MMRN2 complex was shown to stabilize CD93 in filopodia and drive β1 integrin/FAK activation and fibronectin fibrillogenesis, linking the interaction to matrix assembly and vessel maturation.

   Evidence Filopodia imaging, interaction assays, β1 integrin and FAK readouts, fibronectin fibrillogenesis, CD93-deficient mouse tumors

   PMID:29763414

   Open questions at the time

   • Connection between integrin activation and downstream vessel phenotype incompletely defined
   • Role of EMI/C1q domains not addressed
9. 2019 High

   To establish MMRN2's role in barrier function, loss-of-function in vitro and Mmrn2-/- mice revealed junctional instability via VEGFR2 Tyr951/Tyr949, Src, and VE-cadherin phosphorylation, defining MMRN2 as a suppressor of permeability signaling.

   Evidence RNAi, phospho-specific assays, permeability assays, Mmrn2-/- mice, tumor xenograft and chemotherapy delivery

   PMID:31422156

   Open questions at the time

   • Receptor mediating the permeability-suppressing signal not pinpointed
   • Link between ligand sequestration and junctional signaling not unified
10. 2020 High

    Extending MMRN2 beyond the vasculature, it was shown to signal through CD93 in cortical neural stem cells via β-Catenin→ZFP503 to repress Gfap and astrogenesis, demonstrating a developmental signaling role.

    Evidence Cd93 knockout mice, MMRN2 treatment, β-Catenin translocation, Zfp503 reporter, Gfap promoter ChIP, astrogenesis quantification

    PMID:32291340

    Open questions at the time

    • Proximal phosphorylation events linking CD93 to β-Catenin not defined
    • Generality to other neural lineages unknown
11. 2023 Medium

    To capture post-transcriptional and disease-context regulation, MMRN2 was shown to be repressed by miR-1910-5p (driving permeability) and to mediate CD248-dependent anti-angiogenic VEGFR2 suppression in systemic sclerosis.

    Evidence Luciferase 3'UTR reporter and antagomir corneal model; SSc skin immunofluorescence and CD248 shRNA co-culture with VEGFR2 readout

    PMID:35916713 PMID:37040097

    Open questions at the time

    • Disease relevance largely model-based
    • Other regulators of MMRN2 abundance not characterized
12. 2023 Medium

    To probe MMRN2 in cancer cell biology, CD93-MMRN2-integrin β1 signaling was shown to activate PI3K/AKT/SP2 driving migration, invasion, and vasculogenic mimicry in breast cancer.

    Evidence Co-IP, siRNA, integrin β1 activation, PI3K/AKT/SP2 phospho-assays, Transwell, vasculogenic mimicry, xenograft

    PMID:38511888

    Open questions at the time

    • Single-lab Co-IP without reciprocal structural validation
    • Direct vs indirect role of MMRN2 in cancer-cell-intrinsic signaling unclear
13. 2024 Medium

    Extending the CLEC14A-MMRN2 axis to skeletal biology, blockade of the interaction phenocopied Clec14a-/- accelerated osteoblast maturation and bone formation in type-H capillaries.

    Evidence Clec14a-/- mice, antibody blockade, bone density and osteoblast maturation assays

    PMID:39394430

    Open questions at the time

    • Mechanism linking endothelial interaction to osteoblast maturation not defined
    • MMRN2-specific contribution vs CLEC14A not separated

• How the distinct receptor engagements (VEGF-A sequestration, CLEC14A, CD93, CD248) are integrated into a unified output controlling angiostasis versus maturation, and the structural basis of the multi-subunit complex, remain open.
• No high-resolution structure of MMRN2 or its receptor complexes
• Functional roles of the EMI and C1q-like domains not assigned
• Integration of ligand-sequestration and receptor-signaling activities unresolved